{4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid ethyl ester | 1157579-86-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid ethyl ester
• 英文别名: {4-[(1R,3S)-3-{[(1R)-1-(Naphthalen-1-yl)ethyl]amino}cyclopentyl]phenoxy}acetic acid ethyl ester；ethyl 2-[4-[(1R,3S)-3-[[(1R)-1-naphthalen-1-ylethyl]amino]cyclopentyl]phenoxy]acetate
• CAS: 1157579-86-6
• 化学式: C₂₇H₃₁NO₃
• 分子量: 417.548
• InChiKey: HNTGYMTZGIDWHP-PTUXOGIPSA-N

物化性质

• 沸点：
  562.6±50.0 °C(predicted)
• 密度：
  1.15±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid ethyl ester 在 盐酸 、 水 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 {4-[(1R,3S)-3-{[(1R)-1-(Naphthalen-1-yl)ethyl]amino}cyclopentyl]phenoxy}acetic acid hydrochloride
  参考文献：
  名称：

  CYCLOALKYLAMINE DERIVATIVE

  摘要：

  公开号：

  EP2341044B1
• 作为产物：
  描述：

  (1S,3R)-3-[4-(benzyloxy)phenyl]-N-[(1R)-1-(naphthalen-1-yl)ethyl]cyclopentanamine 在 palladium 10% on activated carbon 氢气 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 {4-[3-((R)-1-naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid ethyl ester
  参考文献：
  名称：

  CYCLOALKYLAMINE DERIVATIVE

  摘要：

  公开号：

  EP2341044B1

文献信息

• CYCLOALKYLAMINE DERIVATIVES
  申请人：Marumoto Shinji

  公开号：US20120295943A9

  公开（公告）日：2012-11-22

  Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R 1a and R 1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R 2a and R 2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.

  提供了一种治疗甲状旁腺功能亢进、肾性骨营养不良、高钙血症等疾病的治疗剂，具有CaSR激活（激动剂）作用。该化合物由以下通式（1）表示：[其中，通式（1）中的部分结构Ar表示苯基或萘基；R1a和R1b相同或不同，表示氢原子，卤素基团或类似物；R2a和R2b相同或不同，表示氢原子，卤素基团或类似物；A表示单键，氧原子或类似物；B表示单键，C1-C4烷二基基团或类似物；Z表示羧基或四唑基；m表示1至3的整数]或其药学上可接受的盐。
• POLYMORPHIC FORM OF A CALCIMIMETIC COMPOUND
  申请人：Ebdrup Søren

  公开号：US20130143846A1

  公开（公告）日：2013-06-06

  The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C 1 -C 6 alkyl alcohol, or alternatively by precipitation from a neutralized saponification reaction mixture following the alkaline hydrolysis of a C 1 -C 6 alkyl ester of 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid.

  本发明涉及钙敏感剂化合物4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-乙酸的结晶多形形式X，其制备方法，通过单晶X射线衍射（XRC）、X射线粉末衍射、衰减全反射傅里叶变换红外（ATR-FTIR）光谱、固态核磁共振（NMR）光谱和差示扫描量热（DSC）的表征方法，以及其使用。本发明还涉及通过在C1-C6烷基醇中饱和溶液中结晶4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-乙酸或通过在碱性水解C1-C6烷基4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-乙酸酯的中和皂化反应混合物中沉淀形成X形式的制备方法。
• Polymorphic form of a calcimimetic compound
  申请人：Ebdrup Søren

  公开号：US08946474B2

  公开（公告）日：2015-02-03

  The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C1-C6 alkyl alcohol, or alternatively by precipitation from a neutralized saponification reaction mixture following the alkaline hydrolysis of a C1-C6 alkyl ester of 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid.

  本发明涉及一种钙摄取调节剂化合物的结晶多型形式X，其化学名称为4-[(1R,3S)-3-((R)-1-萘基-乙基氨基)-环戊基]-苯氧基}-乙酸，以及其制备方法、单晶X射线衍射（XRC）、X射线粉末衍射、衰减全反射傅里叶变换红外（ATR-FTIR）光谱、固体核磁共振（NMR）光谱和差示扫描量热（DSC）的表征方法，以及其用途。本发明还涉及通过在C1-C6烷基醇中的饱和溶液中结晶4-[(1R,3S)-3-((R)-1-萘基-乙基氨基)-环戊基]-苯氧基}-乙酸，或通过在中性皂化反应混合物中碱性水解C1-C6烷基酯的方法制备形式X。
• NEW POLYMORPHIC FORM OF A CALCIMIMETIC COMPOUND
  申请人：Ebdrup Soren

  公开号：US20130131023A1

  公开（公告）日：2013-05-23

  The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form C by crystallization from a saturated solution of 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in the presence of crystallization seeds of Form C, or alternatively by conversion of an amorphous starting material into the different crystalline polymorphic Form X by crystallization of 4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, followed by a solid solution transformation thereof into the desired polymorphic Form C.

  本发明涉及一种钙敏感化合物的结晶多形C，即4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid，以及其制备方法，通过单晶X射线衍射（XRC）、X射线粉末衍射、衰减全反射傅里叶变换红外（ATR-FTIR）光谱、固态核磁共振（NMR）光谱和差示扫描量热（DSC）对其进行表征的方法，以及其用途。本发明还涉及通过在存在多形C结晶种子的饱和溶液中结晶4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid，或通过将非晶起始物质结晶为不同的结晶多形X，然后通过固体溶液转化将其转化为所需的多形C的制备方法。
• Cycloalkylamne derivatives
  申请人：Marumoto Shinji

  公开号：US09133140B2

  公开（公告）日：2015-09-15

  Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R1a and R1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R2a and R2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.

  提供了一种治疗甲状旁腺功能亢进症、肾性骨营养不良、高钙血症等疾病的治疗剂，其具有CaSR激活（激动剂）作用。化合物由以下通式（1）表示：[其中，通式（1）中的部分结构Ar表示苯基或萘基；R1a和R1b相同或不同，表示氢原子，卤素基或类似物；R2a和R2b相同或不同，表示氢原子，卤素基或类似物；A表示单键，氧原子或类似物；B表示单键，C1-C4烷二基基团或类似物；Z表示羧基或四唑基；m表示1到3的整数]或其药学上可接受的盐。